江苏联环药业股份有限公司 关于控股子公司获得《药品补充申请批准通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）控股子公司新乡市常乐 制药有限责任公司（以下简称"常乐制药"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的关于布美他尼注射液（以下简称"本 品"或"该药品"）《药品补充申请批准通知书》，现将相关情况公告如下： 1 布美他尼注射液主要适用于：（1）水肿性疾病，包括充血性心力衰竭、肝 硬化、肾脏疾病，与其他药物合用治疗急性肺水肿和急性脑水肿等；（2）高血 压；（3）预防急性肾功能衰竭；（4）高钾血症及高钙血症；（5）稀释性低钠 血症；（6）抗利尿激素分泌过多症；（7）急性药物毒物中毒等。截至本公告 披露日，该药品 2024 年度国内样本医院销售额约为 2.90 亿元，2025 年前三季 度国内样本医院销售额约为 1.03 亿元（数据来源于摩熵·医药数据库）。 证券代码：600513 证券简称：联环药业 公告编号：2026-015 药品名称 布 ...

Market Overview - The A-share market showed a strong rebound today, with the Shanghai Composite Index rising by 0.24%, while Japanese and Korean markets fell by nearly 3% each, indicating a competitive advantage for China [1] - The total market turnover reached 19,277.83 billion yuan, an increase of 637.87 billion yuan compared to the previous day, with over 2,800 stocks rising [21] Sector Performance - The aluminum sector led the gains, with companies like Tianshan Aluminum and Chang Aluminum hitting the daily limit. This surge is attributed to attacks on two Middle Eastern aluminum producers, which disrupted global aluminum supply chains [21][31] - The pharmaceutical sector continued to perform well, with stocks like Meinuo Pharma achieving five consecutive limits. The first quarter saw China's innovative drug licensing transactions exceed $60 billion, nearing half of last year's total [21] - The aerospace sector also saw increased activity, with companies like Shenjian Co. and Zengsheng Technology experiencing multiple limit-ups due to recent contract wins and upcoming launches [21] Company Updates - Maiwei Co. experienced a significant drop in stock price, attributed to market rumors regarding export restrictions on equipment and weak first-quarter performance expectations. However, the company has completed the first phase of equipment delivery for HJT production lines in the U.S. [16][18] - The optical fiber sector showed strong performance, with companies like Hengtong Optic-Electric and Changfei Optic-Fiber seeing stock price increases due to rising prices from operators and strong demand from data centers [19][23] - The agricultural sector also saw gains, driven by rising energy prices impacting fertilizer and logistics costs, which in turn raised expectations for agricultural product prices [23] Financial Performance - Zhaoyan New Drug reported a revenue of 1.658 billion yuan for 2025, a decrease of 17.87% year-on-year, but a net profit increase of 302.08% to 298 million yuan [27] - New Sharp Co. expects first-quarter revenue for 2026 to be between 1 billion and 1.15 billion yuan, a year-on-year increase of 89.28% to 117.68% [27] - Huazhi Precision anticipates a first-quarter net profit of 150 to 190 million yuan for 2026, reflecting a year-on-year growth of 413.28% to 550.15% [27] Industry Insights - Goldman Sachs has downgraded the target for the MSCI China Index and the CSI 300 Index by 5% and 4%, respectively, indicating a potential price return of 24% and 12% over the next 12 months [12] - The global economic backdrop is expected to lower the fair value of Chinese stocks by approximately 5%, with 2% attributed to profit deterioration and 3-4% due to a decline in the price-to-earnings ratio [11]

我公司作为江苏联环药业股份有限公司(以下简称"联环药业") 的控股股东,截至目前,除联环药业在指定媒体已披露信息之外,我 公司不存在影响联环药业股票价格异常波动的重大事项;不存在应披 露而未披露的重大信息,包括但不限于重大资产重组、股份发行、上 市公司收购、债务重组、业务重组、资产剥离、资产注入、股份回购、 股权激励、引进战略投资者等重大事项。 同时,经与扬州市国有资产监督管理委员会(以下简称"扬州市 国资委"）确认,截至目前,扬州市国资委作为联环药业的实际控制 人,除联环药业在指定媒体已披露信息之外,扬州市国资委不存在影 响联环药业股票价格异常波动的重大事项:不存在应披露而未披露的 重大信息,包括但不限于重大资产重组、股份发行、上市公司收购、 债务重组、业务重组、资产剥离、资产注入、股份回购、股权激励、 引进战略投资者等重大事项。 我公司在本次股票异常波动期间未买卖联环药业股票。 江苏联环药业集团有限公司 关于江苏联环药业股份有限公司股票交易 异常波动询证函的回复 江苏联环药业股份有限公司: 《江苏联环药业股份有限公司关于公司股票交易异常波动的询 证函》收悉,经自查确认,现回复如下: 我公司亦将严格遵守《上 ...

证券代码：600513 证券简称：联环药业 公告编号：2026-013 江苏联环药业股份有限公司 关于控股子公司获得《药品补充申请批准通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）控股子公司新乡市常乐 制药有限责任公司（以下简称"常乐制药"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的关于氯化钾注射液（以下简称"本品" 或"该药品"）《药品补充申请批准通知书》，现将相关情况公告如下： 1 药品名称 氯化钾注射液 剂型 注射剂 注册分类 化学药品 包装规格 5 支/盒 规格 10ml:1.5g 受理号 CYHB2550180 通知书编号 2026B01930 原药品批准文号 国药准字 H20184104 申请内容 申请增加 10ml:1.5g 规格，同时申请仿制药质量和疗效一致性评价。 上市许可持有人 名称：新乡市常乐制药有限责任公司 地址：河南省辉县市东郊 生产企业 名称：上海浦津林州制药有限公司 地址：林州市兴林路西段 审批结论 根据《中华人 ...

证券代码：600513 证券简称：联环药业 公告编号：2026-014 江苏联环药业股份有限公司 股票交易异常波动的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 交易异常波动。 二、公司关注并核实的相关情况 重要内容提示： 1、江苏联环药业股份有限公司（以下简称"公司"）股票于 2026 年 3 月 27 日、3 月 30 日连续两个交易日内收盘价格涨幅偏离值累计超过 20%，根据《上海 证券交易所交易规则》的有关规定，属于股票交易异常波动，敬请广大投资者注 意二级市场交易风险，理性决策，审慎投资。 2、公司 2025 年年度实现归属于上市公司股东的净利润区间预计为 -9,900.00 万元人民币至-8,300.00 万元人民币，与上年同期相比将减少 16,666.00 万元人民币至 18,316.00 万元人民币，业绩由盈转亏，敬请广大投资 者注意二级市场交易风险，理性决策，审慎投资。 3、公司关注到市场上针对 LH-1801 项目的相关信息，LH-1801 项目短期内 不能取得上市批准，后续能否获得上市批准以及获批上 ...

Market Overview - A-shares opened lower but rose throughout the day, with major indices collectively increasing and turning positive [1] - The A-share market saw a surge in the non-ferrous metals, pharmaceutical biology, and basic chemicals sectors, leading to a wave of stocks hitting the daily limit [1][4] A-share Performance - By the end of the morning session, the Shanghai Composite Index rose by 0.26%, the Shenzhen Component Index by 0.93%, the ChiNext Index by 0.83%, and the Sci-Tech Innovation Index by 1.08% [4] - The non-ferrous metals sector led the gains with an increase of 2.6%, with multiple stocks hitting the daily limit, including Shenzhen New Star, Haixing Co., Rongjie Co., Yunnan Zhiye, and others [4][5] Pharmaceutical Sector - The pharmaceutical biology sector also performed well, with stocks like Hotgen Biotech, Yinuo Si, Shutaishen, and Huana Pharmaceutical seeing increases of over 10% [6][7] - Notable stocks in this sector included Hotgen Biotech with a rise of 14.70% and Shutaishen with an increase of 11.50% [7] Basic Chemicals Sector - The basic chemicals sector experienced significant gains, with stocks such as Keta Biotech and Shandong Haihua hitting the daily limit [8][9] - Keta Biotech saw a remarkable increase of 19.99%, while other stocks in the sector also posted gains around 10% [9] New Listings - A new stock, Puan Medical, was listed today, with its price surging over 170% at one point during the session [11][12] - Puan Medical specializes in diabetes care and related medical devices, with a projected increase in global insulin pen needle sales from 8.81 billion units in 2022 to 9.97 billion units by 2024 [12] Hong Kong Market - The Hong Kong market experienced narrow fluctuations, with China Longgong's stock surging over 20% during the morning session [13][15] - China Longgong reported a total revenue of RMB 11.215 billion for the year 2025, reflecting a year-on-year growth of 9.81%, with significant contributions from electric loaders and export products [15][16]

Market Overview - The A-share market opened lower but rebounded, with all three major indices turning positive. The half-day trading volume in the Shanghai and Shenzhen markets was 1.14 trillion, a decrease of 84.3 billion compared to the previous trading day [1]. Stock Performance - Over 3,700 stocks in the market rose, indicating a broad-based rally [2]. Sector Highlights - The lithium mining sector saw significant gains, with Rongjie Co. achieving a four-day consecutive rise, while Jiangte Electric, Jinyuan Co., and Shengxin Lithium Energy hit the daily limit [3]. - The pharmaceutical sector also performed strongly, with Keta Bio reaching the daily limit, Meinuohua achieving five gains in six days, and Wanbangde recording three gains in four days. Lianhuan Pharmaceutical and Shuanglu Pharmaceutical also hit the daily limit [3]. - The chemical sector was active, with Sully Co., Lubai Chemical, and Jinzheng all reaching the daily limit [3]. Declines - In contrast, several stocks in the green energy sector experienced declines, with Liaoning Energy hitting the daily limit down, and both Jieneng Wind Power and Haili Wind Power seeing significant drops [4]. Closing Summary - By the end of the trading session, the Shanghai Composite Index rose by 0.26%, the Shenzhen Component Index increased by 0.93%, and the ChiNext Index was up by 0.83% [5].

证券代码：600513 证券简称：联环药业 公告编号：2026-012 江苏联环药业股份有限公司 关于控股子公司获得《药品补充申请批准通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 尼可地尔片用于治疗心绞痛。截至本公告披露日，该药品 2024 年度国内样 本医院销售额约为 6.35 亿元（数据来源于摩熵·医药数据库）。 截至本公告披露日，常乐制药针对该药品的研发投入约为人民币 720.00 万 元（未经审计）。 截至本公告披露日，此为常乐制药 2026 年获得的首个生产批件。 三、对公司的影响及风险提示 本次常乐制药获得尼可地尔片《药品补充申请批准通知书》，进一步丰富 公司及子公司产品品种，有利于提升公司及子公司市场竞争力。上述《药品补 充申请批准通知书》的取得预计不会对公司及子公司近期经营业绩产生重大影 响。由于药品销售受到国家政策、市场环境、市场接受度、市场竞争力等因素 影响，存在不确定性，敬请广大投资者审慎决策，注意投资风险。 江苏联环药业股份有限公司（以下简称"公司"）控股子公司新乡市常乐 制药有限责任 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的关于间苯三酚注射液（以下 简称"本品"）的《药品注册证书》，现将相关情况公告如下： 二、药品的其他情况 1 药品名称 间苯三酚注射液 剂型 注射剂 规格 4ml:40mg（按 C6H6O3•2H2O 计） 申请事项 药品注册（境内生产） 注册分类 化学药品 4 类 处方药/非处方药 处方药 受理号 CYHS2403208 证书编号 2026S00646 药品批准文号 国药准字 H20263534 上市许可持有人 名称：江苏联环药业股份有限公司 地址：江苏省扬州市扬州生物健康产业园健康一路 9 号 生产企业 名称：江苏联环药业股份有限公司 地址：江苏省扬州市扬州生物健康产业园健康一路 9 号 审批结论 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、 说明书、标签及生产工艺照所附执行。药品生产企业应当符 ...

Core Viewpoint - The company has received a drug registration certificate for Tadalafil 20mg tablets from the Ghana Food and Drug Administration, marking a significant step in its international market expansion [1][3]. Group 1: Drug Registration Details - Drug Name: TADALAFIL 20mg TABLETS - Dosage Form: Tablet - Specification: 20mg - Registration Number: FDA/GD.255-120251 - Certificate Number: FDA-GH-77157971 - Manufacturer: Jiangsu Lianhuan Pharmaceutical Co., Ltd. - Address: No. 9, Health Road, Yangzhou Biohealth Industry Park, Yangzhou, Jiangsu Province - Validity Period: Until December 31, 2030 [1]. Group 2: Market Position and Financial Impact - The company is the only Chinese enterprise holding the Tadalafil 20mg drug registration certificate in Ghana [2]. - The sales revenue for Tadalafil tablets in 2024 is projected to be 23.0793 million RMB [1]. - The registration allows for legal sales in Ghana, but the expected revenue impact on the company's overall performance is minimal due to the current lack of sales in the region [3].